Can-Fite BioPharma (NYSE:CANF – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.
Separately, EF Hutton Acquisition Co. I upgraded shares of Can-Fite BioPharma to a “strong-buy” rating in a research report on Wednesday, July 17th.
Check Out Our Latest Stock Report on Can-Fite BioPharma
Can-Fite BioPharma Trading Down 3.7 %
Institutional Trading of Can-Fite BioPharma
A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC lifted its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 35.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the period. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. 21.00% of the stock is owned by institutional investors.
About Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
Featured Articles
- Five stocks we like better than Can-Fite BioPharma
- High Flyers: 3 Natural Gas Stocks for March 2022
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- How to Invest in Blue Chip Stocks
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.